Celldex Therapeutics CLDX Net unrealized gains (losses) on securities still held
Net unrealized gains (losses) on securities still held at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's net unrealized gains (losses) on securities still held.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's net unrealized gains (losses) on securities still held?
- Celldex Therapeutics (CLDX) reported net unrealized gains (losses) on securities still held of -$1.1M in Q1 2026.
- How has Celldex Therapeutics's net unrealized gains (losses) on securities still held changed year-over-year?
- Celldex Therapeutics's net unrealized gains (losses) on securities still held decreased by 534.6% year-over-year, from $254K to -$1.1M.
- What does net unrealized gains (losses) on securities still held mean?
- This metric captures the change in the fair value of investment securities held by the company that have not yet been sold. It reflects unrealized gains or losses that are recognized in other comprehensive income rather than net income. This provides insight into the volatility and performance of the company's investment portfolio outside of its primary business operations.